| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 83.3 | 45.9 |
| Net income | -49.4 | -60.7 |
| EPS (diluted, $ a share) | $-0.55 | $-0.70 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +81.6% |
|---|---|
| Operating margin | -50.3% |
10-Q filed with the SEC, NASDAQ: SNDX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Syndax Pharmaceuticals Inc: key numbers
- Share price
- $9.13Close, Nov 16
- Market cap
- $815M
- Shares outstanding
- 89.3MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Syndax Pharmaceuticals Inc
All →Syndax Pharmaceuticals Financial Results
Syndax Pharmaceuticals reported Q3 2026 total revenue of $83.3 million, an 82% year-over-year increase driven by strong sales of Revuforj and Niktimvo. The company also announced a leadership transition with Aaron A. Ondrey appointed as CFO effective November 9, 2026, succeeding the retiring Keith A. Goldan.
“We delivered another quarter of strong commercial results, generating $83 million in total revenue to Syndax. Revuforj net revenue grew to $61 million, driven by a 20% increase in new patients and an increasing number of patients on therapy in the post-transplant setting.”
Michael A. Metzger, Chief Executive Officer
“We look forward to sharing new Revuforj combination data in the fourth quarter that reinforce our confidence that our ongoing pivotal frontline trials could transform the treatment paradigm for newly diagnosed AML. We remain well positioned to be the first to deliver a menin inhibitor in the frontline, unlocking a multi-billion-dollar opportunity.”
Michael A. Metzger, Chief Executive Officer
Syndax Pharmaceuticals Director Dennis Podlesak Sells $114K of Stock
Dennis Podlesak, Director, sold 8,000 shares of Syndax Pharmaceuticals Inc at $14.21 a share, worth $114K in total on Oct 29, 2026. Shares held after the trade: 239,763 (-3.2%).
- Value
- $114K
- Shares
- 8,000
- Price
- $14.21
- Role
- Director
- Holding change
- -3.2%
- Trade date
- Oct 29, 2026